X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CADILA HEALTHCARE - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CADILA HEALTHCARE IPCA LABS/
CADILA HEALTHCARE
 
P/E (TTM) x 27.7 19.4 142.7% View Chart
P/BV x 3.3 4.6 71.4% View Chart
Dividend Yield % 0.1 0.9 16.0%  

Financials

 IPCA LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    IPCA LABS
Mar-18
CADILA HEALTHCARE
Mar-18
IPCA LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs695558 124.6%   
Low Rs400362 110.7%   
Sales per share (Unadj.) Rs260.2116.3 223.7%  
Earnings per share (Unadj.) Rs19.017.9 106.2%  
Cash flow per share (Unadj.) Rs33.123.1 142.9%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.20.8 24.0%  
Book value per share (Unadj.) Rs213.085.4 249.4%  
Shares outstanding (eoy) m126.201,023.74 12.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.0 53.2%   
Avg P/E ratio x28.925.7 112.2%  
P/CF ratio (eoy) x16.619.9 83.4%  
Price / Book Value ratio x2.65.4 47.8%  
Dividend payout %5.319.6 26.9%   
Avg Mkt Cap Rs m69,120470,664 14.7%   
No. of employees `00013.311.8 112.1%   
Total wages/salary Rs m7,35918,545 39.7%   
Avg. sales/employee Rs Th2,477.410,072.7 24.6%   
Avg. wages/employee Rs Th555.21,569.1 35.4%   
Avg. net profit/employee Rs Th180.61,547.7 11.7%   
INCOME DATA
Net Sales Rs m32,836119,049 27.6%  
Other income Rs m4181,132 36.9%   
Total revenues Rs m33,254120,181 27.7%   
Gross profit Rs m4,50528,475 15.8%  
Depreciation Rs m1,7775,388 33.0%   
Interest Rs m240911 26.4%   
Profit before tax Rs m2,90523,308 12.5%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5115,644 9.1%   
Profit after tax Rs m2,39418,292 13.1%  
Gross profit margin %13.723.9 57.4%  
Effective tax rate %17.624.2 72.6%   
Net profit margin %7.315.4 47.5%  
BALANCE SHEET DATA
Current assets Rs m19,45582,005 23.7%   
Current liabilities Rs m10,07660,720 16.6%   
Net working cap to sales %28.617.9 159.8%  
Current ratio x1.91.4 143.0%  
Inventory Days Days9873 133.8%  
Debtors Days Days6798 68.1%  
Net fixed assets Rs m20,26083,703 24.2%   
Share capital Rs m2521,024 24.6%   
"Free" reserves Rs m26,63386,421 30.8%   
Net worth Rs m26,88687,445 30.7%   
Long term debt Rs m2,34025,551 9.2%   
Total assets Rs m41,173180,653 22.8%  
Interest coverage x13.126.6 49.3%   
Debt to equity ratio x0.10.3 29.8%  
Sales to assets ratio x0.80.7 121.0%   
Return on assets %6.410.6 60.2%  
Return on equity %8.920.9 42.6%  
Return on capital %10.822.0 48.9%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64242,683 36.6%   
Fx outflow Rs m4,88411,242 43.4%   
Net fx Rs m10,75931,441 34.2%   
CASH FLOW
From Operations Rs m3,4119,193 37.1%  
From Investments Rs m-1,354-9,737 13.9%  
From Financial Activity Rs m-1,304515 -253.2%  
Net Cashflow Rs m753-29 -2,597.2%  

Share Holding

Indian Promoters % 45.9 74.8 61.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.3 137.3%  
FIIs % 25.3 5.9 428.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 11.0 158.2%  
Shareholders   36,892 44,069 83.7%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 24, 2018 10:53 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS